Correlation Between AptaBio Therapeutics and Mercury

Can any of the company-specific risk be diversified away by investing in both AptaBio Therapeutics and Mercury at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AptaBio Therapeutics and Mercury into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between AptaBio Therapeutics and Mercury, you can compare the effects of market volatilities on AptaBio Therapeutics and Mercury and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AptaBio Therapeutics with a short position of Mercury. Check out your portfolio center. Please also check ongoing floating volatility patterns of AptaBio Therapeutics and Mercury.

Diversification Opportunities for AptaBio Therapeutics and Mercury

0.19

Correlation Coefficient

AptaBio Therapeutics  Mercury

Average diversification

The 3 months correlation between AptaBio and Mercury is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding AptaBio Therapeutics and Mercury in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mercury and AptaBio Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AptaBio Therapeutics are associated (or correlated) with Mercury. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mercury has no effect on the direction of AptaBio Therapeutics i.e., AptaBio Therapeutics and Mercury go up and down completely randomly.

Pair Corralation between AptaBio Therapeutics and Mercury

Assuming the 90 days trading horizon AptaBio Therapeutics is expected to generate 1.63 times more return on investment than Mercury. However, AptaBio Therapeutics is 1.63 times more volatile than Mercury. It trades about 0.08 of its potential returns per unit of risk. Mercury is currently generating about -0.14 per unit of risk. If you would invest  626,000  in AptaBio Therapeutics on December 25, 2024 and sell it today you would earn a total of  90,000  from holding AptaBio Therapeutics or generate 14.38% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

AptaBio Therapeutics  vs.  Mercury

AptaBio Therapeutics

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in AptaBio Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, AptaBio Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Mercury

Risk-Adjusted Performance

Very Weak

Over the last 90 days Mercury has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with AptaBio Therapeutics and Mercury

The main advantage of trading using opposite AptaBio Therapeutics and Mercury positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AptaBio Therapeutics position performs unexpectedly, Mercury can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mercury will offset losses from the drop in Mercury's long position.

The idea behind AptaBio Therapeutics and Mercury pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.